ERLEADA® + ADT demonstrates a consistent, acceptable safety profile[2]

ERLEADA® is indicated in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), in combination with ADT.[1]

Medical castration with gonadotropin-releasing hormone analogue (GnRHa) should be continued during ERLEADA® treatment in patients who have not undergone surgical castration.[1]

Dr using a tablet

ERLEADA® is a practical and convenient treatment for you and your patients[1]

Calculator icon
240 mg once-daily dosing
Food icon
Can be taken with or without fooda
Home icon
Convenient oral treatment at homeb

aTablets should be swallowed whole.[1]

bNo additional laboratory monitoring requirements beyond routine assessments for AEs.[1]

You can delay the threat of castration resistance in mHSPC with ERLEADA® + ADT 
– the practical, once-daily, oral treatment[1][2]

Click below to find out more about the clinical benefits with ERLEADA® + ADT:

Increase survival and delay progression

Treat early with ERLEADA® + ADT to delay progression and extend life for your mHSPC patients vs. placebo + ADT[2]

Treat early in a broad range of mHSPC patients

Extend life across a broad range of mHSPC patients with ERLEADA® + ADT[2]

Maintain QoL

Push back on progression and maintain QoL in mHSPC[2]


ADT, androgen deprivation therapy. AE, adverse event. mHSPC, metastatic hormone-sensitive prostate cancer.


ERLEADA®. Summary of Product Characteristics (April 2021). Janssen-Cilag Limited. Available at: https://www.ema.europa.eu/en/documents/product-information/erleada-epar-product-information_en.pdf. Accessed: September 2021.
Chi KN, et al. J Clin Oncol 2021 Apr 29:JCO2003488. doi: 10.1200/JCO.20.03488.
CP-282954 - January 2022